UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549



	FORM 8-K

~~Pursuant~~CURRENT REPORT Pursuant to Section 13 or 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of ~~report~~Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): ~~September~~ ~~8. 2016~~May 19, 2017

~~Ember~~EMBER ~~Therapeutics~~THERAPEUTICS, ~~Inc~~INC.

(Exact name of registrant as specified in ~~its~~ charter)

Delaware	033-13474-NY	01-3341552
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation)	(Commission File Number)	Identification No.)

135 East 57th Street, 24th Floor New York, NY	10022
(Address of principal executive offices)	(Zip Code)

135 East 57^thStreet, 24 ^thFloor
New York, New York10022
(Address and Zip Code of Principal Executive Offices)

(646) 406-6243(Registrant’s ~~telephone~~ ~~number~~Telephone Number, including area code~~: (646~~) ~~406-6243~~

~~___________________________________________________~~ n/a(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last report~~Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~[ ]~~o Written communications pursuant to Rule 425 under the Securities Act (17 ~~CFR~~CF R. 230.425)

~~[ ]~~o Soliciting ~~material~~ material pursuant to Rule 14a-12 under the Exchange Act (17 CFR. 240.~~14a~~14-1212a)

~~[ ]~~ o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR . 240.14d-2(b))

~~[ ]~~ o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR. 240.~~13e~~13-4e4(c))

~~SECTION 1-~~Item ~~REGISTRANT’S~~8.01 ~~BUSINESS~~– ~~AND~~Other ~~OPERATIONS~~Events

~~Item~~On May 19, 2017, Ember Therapeutics, Inc. (“Ember Therapeutics”) 1entered into a Contribution Agreement (“DermaSilk Agreement”) with DermaSilk Brands, Inc.01 ~~Entry~~(“DermaSilk”), ~~Into~~a ADelaware ~~Material~~corporation. ~~Definitive~~Pursuant to the DermaSilk Agreement, DermaSilk acquired the sole ownership interest in DermaSilk Brands business, including all assets and liabilities related thereto, and DermaSilk became a wholly owned subsidiary of Ember Therapeutics. The DermaSilk Agreement isa ttached as Exhibit 99.1.

~~On September~~Also 8on May 19, ~~2016~~2017, we Ember Therapeutics entered into an ~~Asset~~a ~~Purchase~~Contribution Agreement (~~the~~“Migralex "Agreement"”) with ~~Midwood~~ ~~Distributors~~Migralex, Inc., (“Migralex”) a ~~New~~ ~~York corporation~~Delaware ~~("Midwood Distributors")~~corporation. ~~Under~~ Pursuant to the Migralex Agreement, weMigralex acquired the sole ownership interest in the Migralex business, including all assets and liabilities related ~~to Dermasilk Brands~~thereto, and Migralex became a ~~line~~wholly ofowned ~~anti-aging~~subsidiary ~~skin~~of Ember ~~care~~Therapeutics. ~~products~~The MigralexAgreement is attached as Exhibit 99.1.

~~Under the~~Item ~~Agreement,~~9.01 ~~we have~~Financial ~~acquired~~Statements ~~all material assets currently owned by Dermasilk, including all inventory, raw materials, work in process, packaging, the toll free number, hardware~~ and ~~software~~Exhibits used for ordering and customer support, all intellectual property, websites, domain names, accounts receivable and vendor credits, contracts, and all marketing and promotional information and materials.

~~The purchase~~(d) ~~price~~Exhibits ~~for the Dermasilk assets consisted of common stock and warrants, paid as follows:~~

• 2,105,263 shares of common stock at purchase price of$0.95.


Exhibits No.	Description
99.1	Contribution Agreement dated as of May 19, 2017, by and between Ember Therapeutics, Inc. and DermaSilk Brands, Inc.
99.2	Contribution Agreement dated as of May 19, 2017, by and between Ember Therapeutics, Inc. and Migralex, Inc.

In addition, we agreed to assume certain liabilities of Dermasilk arising under certain contracts assumed as part of the asset purchase.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
10.1	Asset Purchase Agreement with Midwood Distributors Inc. for Dermasilk Brand and assets

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant has~~Registrant has duly caused this ~~report~~Form 8-K Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July ~~September 26~~11, ~~2016~~2017

EMBER THERAPEUTICS, INC. By: ~~/s/~~Name: Joseph Hernandez Title: Executive Chairman

Joseph Hernandez

Executive Chairman

Filing Compare · EMBER THERAPEUTICS, INC. - NY